Sarcoma Smart

Breakthroughs in rare cancers start with research funding. Support from SFA enabled Dr. Karen Pollok, PhD, to test a promising combination therapy for osteosarcoma that has spread or no longer responds to standard treatments. Because these drugs are already used in other cancers, this research could accelerate safer, more effective treatments. Investing in rare disease research today makes better treatments possible. We are proud to support researchers like Dr. Pollok who dedicate their careers to turning discovery into progress. Help us fund the next breakthrough: buff.ly/XM8AXSR

Today is World Cancer Day, an international awareness day that brings the global community together to advance progress against cancer. Sarcoma is rare, complex, and often overlooked, yet it affects hundreds of thousands of people around the world each year. Meaningful progress against sarcoma depends on sustained research, funding, and global collaboration. Since 2000, SFA has invested more than $27 million in sarcoma research in the United States and across 13 countries worldwide to help improve outcomes for people affected by sarcoma. On World Cancer Day, and every day, SFA continues to be guided by a bold and unwavering vision: a world where no one dies from sarcoma. #WorldCancerDay #CureSarcoma #SarcomaAwareness #Sarcoma #SFAGlobal

🧠 Pancreatic cancer—cracked? • KRAS + EGFR + STAT3 blocked together • Complete tumor regression in mice • No relapse >200 days • Well tolerated, no major toxicity • Preclinical, not a cure (yet) 📄 Liakia et al, PNAS 2025 #PancreaticCancer #KRAS #STAT3 #PROTAC #MVOnco

🧬 KRAS is no longer “undruggable”. A new Cancer Cell review maps how KRAS inhibitors are reshaping therapy across lung, colorectal, pancreatic and other cancers, and what comes next. 🔬 Essentials
• RAS alterations drive ~20% of cancers worldwide
• KRAS is the most frequent RAS alteration
• KRAS G12C inhibitors proved direct RAS targeting works 💊 Current reality
🟢 Sotorasib & adagrasib show meaningful activity in KRAS G12C NSCLC
🟢 CRC responses improve when combined with anti-EGFR therapy
🟢 Activity emerging in PDAC and other tumors ⚠️ Key challenge
Most patients eventually develop resistance via:
• On-target KRAS mutations
• MAPK pathway reactivation
• RTK feedback signaling
• Non-genetic adaptive escape 🚀 What’s next?
Next-generation strategies include:
• More potent G12C inhibitors
• KRAS G12D & multi-mutation inhibitors
• Isoform-selective and pan-RAS inhibitors
• Rational combination approaches Takeaway: KRAS targeting has moved from breakthrough to optimization phase, with broader RAS inhibition now the next frontier. 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #LungCancer #CRC @OncoAlert @myesmo @esmo_open @ASC

Emerging landscape of KRAS inhibitors in cancer treatment: Cancer Cell cell.com/cancer-cell/fu…

Be sure to catch the latest #SARCTalk with Dr. D'Angelo and Dr. Napolitano about Clear Cell Sarcoma.

🧩 We’re thrilled to collaborate with @StanfordMed and @HHMIJanelia on the Stanford RNA 3D Folding Part 2 Challenge. Help advance the science of RNA structure prediction and push the boundaries of AI for biology. Kickstart your solution with RNAPro, our new baseline model built on key insights from the first competition. 🤔 Can you solve it nvda.ws/4q0FRsw

We've identified a novel class of biomarkers for Alzheimer's detection - using interpretability - with @PrimaMente. How we did it, and how interpretability can power scientific discovery in the age of digital biology: (1/6)

AlphaGenome is out in @nature today along with model weights! 🧬 📄 Paper: nature.com/articles/s4158… 💻 Weights: github.com/google-deepmin… Getting here wasn’t a straight path. We sat down @googledeepmind to discuss the story behind the model, paper & API: youtu.be/V8lhUqKqzUc

SFA is accepting applications for the 2026 Last Mile Sarcoma Research Award. This one-year, $150,000 grant supports sarcoma researchers seeking to strengthen the resubmission of R01 or equivalent proposals focused on advancing the understanding and treatment of sarcoma. Applications are due by February 2, 2026, at 5:00 pm ET. #sarcoma #curesarcoma #sarcomaresearch

🗨️ “Vaccines have done more to improve public health than any other medical intervention.” A Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve patient outcomes and quality of life. hubs.li/Q03YWRxW0

"There is a good size lump in there, it's about 11-12 centimetres." Good to see Johnno come out the other side 🙏 @MarkHoward03 articles.listnr.com/the-howie-game…

@FansAFL youtu.be/YPveWxZGpWc?si…

Western Bulldogs champion Brad Johnson reveals serious cancer scare. The energetic commentator had a lump ‘the size of a small footy’ removed, but he hasn’t won the fight yet. We give Johnno our best wishes on his road to recovery ❤️ 7news.com.au/sport/afl/west…

@triplemfooty @MarkHoward03 youtu.be/YPveWxZGpWc?si…

@FansAFL youtu.be/9Kohvol9c8g?si…

@triplemfooty @MarkHoward03 youtu.be/9Kohvol9c8g?si…

@FOXFOOTY youtu.be/9Kohvol9c8g?si…

Western Bulldogs legend and Fox Footy favourite Brad Johnson has revealed he is on the mend after a serious cancer scare during the 2025 footy season. Lots of love, Johnno 💙🤍❤️ MORE >> bit.ly/3MANBDC

@1116sen @SENBreakfast youtu.be/9Kohvol9c8g?si…

"Scary, but he's going to be okay." Brad Johnson found out he had a rare form of cancer after a Fox Footy skit. Luckily, he got on top of his health issue early. ♥ #AFL | @SENBreakfast

@superfooty youtu.be/9Kohvol9c8g?si…

Brad Johnson has revealed how a bout of bubble soccer on Fox Footy show Bounce led to him discovering and removing a cancerous tumour the size of “a small footy”. DETAILS 👉 bit.ly/4oP8c4D

@codeaflau youtu.be/9Kohvol9c8g?si…

Beloved Western Bulldogs champion Brad Johnson has revealed how a bout of bubble soccer on Bounce led to him discovering and removing a cancerous tumour the size of “a small footy”. DETAILS ▶️ bit.ly/4542mFl